Oklahoma Judge Okays $85m Teva Opioid Out-of-Court Settlement
You may also be interested in...
With a roster of launches planned over coming months, Teva is confident it can keep returning sales by its North American Generics operation in the region of $1bn per quarter.
Teva says paying $85m to settle claims it contributed to opioid abuse in Oklahoma is important in maintaining the stability of the heavily indebted group.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.